Press release
United States Glucagon-like Peptide 1 (GLP-1) Analogues Market Expansion Till 2033: Eli Lilly's Mounjaro Becomes Top-Selling Weight-Loss Treatment | Most Leading Companies are Eli Lilly and Company, Novo Nordisk A/S, Hanmi Pharm. Co.., Ltd, Amgen Inc., Gm
Glucagon-like Peptide 1 (GLP-1) Analogues Market
DataM Intelligence has released its latest report on the "Glucagon like Peptide 1 (GLP-1) Analogues Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.
Novo Nordisk's Oral GLP-1 Pill Nears FDA Approval: A Game Changer in Obesity Care
Novo Nordisk's oral semaglutide (25 mg) from the OASIS-4 trial showed weight loss and cardiometabolic benefits on par with injectable Wegovy. After 64 weeks, 71% of patients achieved normal blood glucose versus 33% on placebo. Expected FDA approval by late 2025, this first oral GLP-1 for chronic weight management could revolutionize obesity treatment with a simple once-daily pill.
Latest M&A
Pfizer acquired Metsera in a $10 billion deal bringing clinical-stage GLP-1 (weekly and monthly) and amylin analogues indicated for obesity into Pfizer's pipeline, intensifying industry competition with Novo Nordisk and Eli Lilly.
Novo Nordisk paid $200 million upfront for The United Laboratories' UBT251, a triple agonist (GLP-1/GIP/glucagon) candidate.
Roche acquired Carmot Therapeutics ($2.7B, closed early 2025), gaining GLP-1/GIP combo drugs to rival industry leaders and expand its pipeline.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?kb
Product Performance (October)
✦ Mounjaro: ₹100 Crore in sales, capturing 15% market share
✦ Competitor A: ₹80 Crore in sales, holding 12% market share
✦ Competitor B: ₹70 Crore in sales, accounting for 10% market share
Clinical Outcomes and Results
✦ Average Weight Loss: Achieved 10-15% reduction from baseline body weight
✦ Blood Sugar Control: Showed notable decrease in HbA1c levels
✦ Appetite Reduction: Demonstrated significant drop in hunger levels
Key Player:
Eli Lilly and Company, Novo Nordisk A/S., Sanofi, AstraZeneca, Boehringer Ingelheim, Inc., Glenmark Pharmaceuticals Ltd., Hanmi Pharm. Co.., Ltd, Amgen Inc., Gmax Biopharm., and Sciwind Biosciences Co., Ltd
Emerging Players
The emerging players in the glucagon-like peptide 1 (GLP-1) analogues market include Gmax Biopharm., Sciwind Biosciences Co., Ltd., Teva Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC (Hikma), Viking Therapeutics, Terns Pharmaceuticals, Inc., Altimmune, AVVA Pharmaceuticals Ltd, LEXICARE PHARMA PVT. LTD., and Natco Pharma Limited, among others.
Key Industry Developments:
In April 2025, Meitheal Pharmaceuticals, Inc. received FDA approval for its liraglutide injection (18 mg/3 mL) and subsequently launched it in the U.S. market.
In February 2025, Biocon Limited, a leading Indian biopharmaceutical company, launched its GLP-1 peptide drug, Liraglutide, in the United Kingdom, strengthening its global footprint in diabetes and obesity care.
In January 2025, Metsera, a New York-based obesity healthcare company, reported positive Phase IIa results for MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, offering a potential advantage over more frequent treatment regimens.
In September 2024, Terns Pharmaceuticals announced positive Phase 1 trial results for TERN-601, a once-daily oral GLP-1 receptor agonist for obesity, confirming its safety, tolerability, and pharmacokinetics in overweight and obese adults.
That same month, Kourtney Kardashian expanded her Lemme wellness brand with the launch of Lemme GLP-1 Daily capsules, promoting health and nutrition through her Poosh lifestyle platform.
In August 2024, Metsera officially launched as a clinical-stage biopharmaceutical firm with US$ 290 million in funding to advance innovative GLP-1-based therapies for obesity and metabolic diseases.
In June 2024, Teva Pharmaceuticals introduced the first generic GLP-1 receptor agonist in the U.S., a liraglutide 1.8 mg formulation, marking a milestone in providing affordable diabetes treatments.
Forecast Projection:
The global Glucagon like Peptide 1 (GLP-1) Analogues market is set to witness strong growth from 2025 to 2032. After maintaining steady momentum in 2024, the market is expected to accelerate as key industry players implement strategic initiatives to boost adoption. Companies that adapt to these emerging trends will be well-positioned to capture new opportunities and enhance their revenue potential throughout the forecast period.
Latest News & Developments
Oral GLP-1s set for FDA review: Novo Nordisk's oral semaglutide 25 mg (weight loss) and oral Rybelsus for CV risk reduction are up for FDA decisions in Q4 2025.
Teva launched first generic Saxenda® (liraglutide) for weight loss in August 2025 after FDA approval-the first generic GLP-1 for obesity, significantly improving affordability.
GLP-1s for new indications: FDA approved Wegovy (semaglutide) for metabolic dysfunction-associated steatohepatitis (MASH) in August 2025. Ozempic's label expansions now include diabetic nephropathy and peripheral artery disease (pending). CagriSema (semaglutide/cagrilintide) and other dual/triple agonists are in late-stage trials.
Market size: GLP-1 analogue market valued at $66.5B in 2025, projected to nearly $880B by 2034, driven by obesity and broader metabolic indication expansions.
Price Competition & Market Trends: Zepbound's price is now $349-$499/mo; insurer and government price negotiations are shaping market dynamics, while insurers sometimes "step edit" patients to preferred products as cost sharing and utilization rise.
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=glucagon-like-peptide-1-analogues-market?kb
Key Segmentations:
By Product: Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Others
By Type: Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist
By Route of Administration: Subcutaneous, Oral
By Application: Type 2 Diabetes Mellitus, Obesity, Others
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/glucagon-like-peptide-1-analogues-market?kb
FAQ's
Q1: How large is the Glucagon like Peptide 1 (GLP-1) Analogues Market?
Ans: The Glucagon like Peptide 1 (GLP-1) Analogues Market size was valued at 62.81 Billion in 2024 and is projected to grow to US$ 299.08 Billion by 2033.
Q2: How quickly is the Glucagon like Peptide 1 (GLP-1) Analogues Market expanding?
Ans: The Glucagon like Peptide 1 (GLP-1) Analogues Market is forecasted to grow at a CAGR of 17.6% between 2025 and 2032, showing Annual growth momentum
Q3: Which regions are dominating the Glucagon like Peptide 1 (GLP-1) Analogues Market and which are fastest-growing?
Ans: North America dominating the Glucagon like Peptide 1 (GLP-1) Analogues market.
FDA & Regulatory Highlights
New FDA guidance (2025) makes obesity itself a qualifying indication, requiring ≥5% placebo-adjusted weight loss for approval and both trial arms to include lifestyle interventions.
Ongoing FDA approvals/expansions for Wegovy, Ozempic, Rybelsus, and others, including for heart failure, chronic kidney disease, and fatty liver disease.
Teva's generic liraglutide (Saxenda) is now available post FDA approval in 2025, increasing competition and price pressures
Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/glucagon-like-peptide-1-analogues-market?kb
Reimbursement Landscape
CMS (Medicare) added Ozempic, Wegovy, and Rybelsus to its list for MFP price negotiation; negotiated prices to take effect in 2027.
US and EU insurers now more frequently reimburse for GLP-1 drugs not only for type 2 diabetes, but also for obesity (coming 2026), heart failure, and chronic kidney disease in certain cases.
Affordability still a concern for uninsured/underinsured and in emerging markets due to high cash price and variable private reimbursement.
Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb
Related Reports:
Weight-Loss Devices Market: https://www.datamintelligence.com/download-sample/weight-loss-devices-market?kb
Weight loss therapeutics Market: https://www.datamintelligence.com/download-sample/weight-loss-therapeutics-market?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
Linkedin: https://www.linkedin.com/company/datam-intelligence/
Twitter: https://x.com/DataM_Research
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Glucagon-like Peptide 1 (GLP-1) Analogues Market Expansion Till 2033: Eli Lilly's Mounjaro Becomes Top-Selling Weight-Loss Treatment | Most Leading Companies are Eli Lilly and Company, Novo Nordisk A/S, Hanmi Pharm. Co.., Ltd, Amgen Inc., Gm here
News-ID: 4261165 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Short-Range Air Surveillance Radar Market to Reach USD 9.56 Billion by 2035 | No …
The global short-range air surveillance radar market was valued at USD 6.42 billion in 2025 and is projected to reach USD 9.56 billion by 2035, growing at a CAGR of 6.5% during the forecast period from 2026 to 2035. The market is witnessing steady growth driven by increasing defense modernization programs, rising concerns over border security, and the growing need for real-time airspace monitoring capabilities. Short-range air surveillance radars play…
Air Ambulance Market to Reach USD 48.90 Billion by 2033 | North America Holds 46 …
The global air ambulance market was valued at USD 18.28 billion in 2025 and is projected to reach USD 48.90 billion by 2033, growing at a CAGR of 10.2% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by the increasing demand for rapid emergency medical transportation, rising incidence of trauma cases, cardiovascular emergencies, and critical care requirements worldwide. Air ambulance services play a…
Healthcare Robotics Systems Market to Reach USD 72.11 Billion by 2035 | North Am …
The global healthcare robotics systems market was valued at USD 14.53 billion in 2025 and is projected to reach USD 72.11 billion by 2035, growing at a CAGR of 17.39% during the forecast period from 2026 to 2035. The market is experiencing robust growth driven by the increasing adoption of robotic technologies across surgical procedures, rehabilitation therapies, hospital logistics, pharmacy automation, and patient care support applications. Healthcare providers are increasingly…
Agricultural Drone Market to Reach USD 50.07 Billion by 2033 | Asia Pacific Hold …
The global agricultural drone market was valued at USD 4.03 billion in 2025 and is projected to reach USD 50.07 billion by 2033, growing at a CAGR of 37.01% during the forecast period from 2026 to 2033. The market is witnessing exceptional growth driven by the increasing adoption of precision agriculture, rising demand for efficient crop monitoring solutions, and growing emphasis on improving agricultural productivity. Agricultural drones are becoming essential…
More Releases for Peptide
Peptide Dropshipping & White Label Peptide Fulfillment Solution Launch | RapidFu …
Image: https://www.globalnewslines.com/uploads/2026/04/a6b799d3d1fc2ae063a8a0793dc74785.jpg
Los Angeles, CA - April 16, 2026 - RapidFulfillment.com, a leading 3PL fulfillment provider, today announced the launch of its Peptide Dropshipping Service Partnership, a turnkey white label peptide fulfillment solution designed to help entrepreneurs, eCommerce brands, and B2B operators enter the rapidly growing peptide market-without inventory, infrastructure, or operational complexity.
This new service provides a fully integrated, end-to-end system combining U.S.-based peptide sourcing, compliant fulfillment, cold storage logistics, and…
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
